1. Academic Validation
  2. Human CYP1A1 inhibition by flavonoids

Human CYP1A1 inhibition by flavonoids

  • Toxicol In Vitro. 2020 Feb:62:104681. doi: 10.1016/j.tiv.2019.104681.
Rebeca Santes-Palacios 1 Ana L Marroquín-Pérez 1 Sandra L Hernández-Ojeda 1 Rafael Camacho-Carranza 1 Tzipe Govezensky 1 J Javier Espinosa-Aguirre 2
Affiliations

Affiliations

  • 1 Instituto de Investigaciones Biomédicas, UNAM, Apartado postal 70228, Ciudad de México, México.
  • 2 Instituto de Investigaciones Biomédicas, UNAM, Apartado postal 70228, Ciudad de México, México. Electronic address: jjea@iibiomedicas.unam.mx.
Abstract

Cytochrome P4501A1 (CYP1A1) is involved in the metabolism of several genotoxic/carcinogenic environmental xenobiotics including polycyclic aromatic hydrocarbons (PAHs) like benzo[a]pyrene. Several authors had proposed CYP1A inhibition as a plausible strategy for Cancer chemoprevention. Using ethoxyresorufin O-deethylase activity (EROD), we tested the inhibitory properties of nine flavonoids: quercetin, miricetin, luteolin, fisetin, morin, kaempferol, 5-hydroxyflavone (5-HF), 3-hydroxyflavone (3-HF), and flavone (F) against human recombinant CYP1A1. The last three compounds exerted the highest inhibitory effect with IC50 values of 0.07, 0.10 and 0.08 μM respectively; the more hydroxyl-groups were present, the lower the potency of inhibition was. Biochemical characterization leads to the conclusion that flavone and its hydroxy derivatives are mixed-type inhibitors. In silico studies have shown that, Phe224 and Other aromatic residues in the human CYP1A1 active site play an important role in flavonoid-CYP interaction, through a π/π stacking between the aminoacid and the flavonoid C-ring. Outside the active site, the three Flavonoids bind preferentially between A and K helices of the Enzyme. Results from the Ames test using human S9 fraction revealed that none of the three compounds was mutagenic. We can consider 5-HF, 3-HF, and F as potential chemopreventive agents against genotoxic damage caused by metabolites resulting from CYP1A1 activity.

Figures
Products